Trump said you could learn something from this man

Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement.

James Peyer Biography and Net Worth

Director of Sensei Biotherapeutics

James Peyer, Ph.D. joined our Board of Directors in 2020 and serves as Chair of the Board. He is the CEO and Founder of Cambrian Biopharma, a Distributed Drug Discovery company developing therapeutics targeting the biology of aging (‘geroscience’). The New York-based company builds, finances, and manages biotech companies. Dr. Peyer founded Cambrian to translate laboratory breakthroughs in the extension of healthy lifespan into the clinic, predicting that the world is entering a revolution in biomedical research by targeting the root causes of aging and age-related disease. Dr. Peyer has spoken on the topic of longevity biotech and investing for The Economist, TEDx, Longevity Leaders, ETH Zurich, and the Max Planck Institute on the Biology of Aging to advance the mission of achieving widespread availability of longevity therapeutics this decade. Before his current role, James was Founder and Managing Partner at Apollo Ventures, one of the major longevity-focused venture capital firms. Apollo has deployed over $20M and raised over $50M in the first three years of operations. He led investments in Cleara Biotech, Aeovian Pharmaceuticals, and Samsara Therapeutics and served on the Board and/or in executive roles for all three companies. Prior to Apollo, James was a consultant at McKinsey & Company, earned his PhD in stem cell biology at UTSW as a National Science Foundation fellow, and received his B.A. with special honors from the University of Chicago.

How do I contact James Peyer?: The corporate mailing address for Dr. Peyer and other Sensei Biotherapeutics executives is 1405 RESEARCH BLVD SUITE 125, ROCKVILLE MD, 20850. Sensei Biotherapeutics can also be reached via phone at 240-243-8000 and via email at [email protected]. Learn More on James Peyer's contact information.
Has James Peyer been buying or selling shares of Sensei Biotherapeutics?: James Peyer has not been actively trading shares of Sensei Biotherapeutics during the last ninety days. Most recently, on Wednesday, March 2nd, James Peyer bought 1,203 shares of Sensei Biotherapeutics stock. The stock was acquired at an average cost of $3.20 per share, with a total value of $3,849.60. Learn More on James Peyer's trading history.
Who are Sensei Biotherapeutics' active insiders?: Sensei Biotherapeutics' insider roster includes James Peyer (Director), Robert Pierce (Insider), and Thomas Ricks (Director). Learn More on Sensei Biotherapeutics' active insiders.

James Peyer Insider Trading History at Sensei Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
3/2/2022	Buy	1,203	$3.20	$3,849.60
2/28/2022	Buy	42	$3.60	$151.20
2/24/2022	Buy	15,000	$3.63	$54,450.00
2/17/2022	Buy	4,949	$4.17	$20,637.33
2/10/2022	Buy	5,000	$4.58	$22,900.00
2/4/2022	Buy	2,500	$4.45	$11,125.00
1/28/2022	Buy	8,900	$4.22	$37,558.00
1/26/2022	Buy	29,900	$4.62	$138,138.00
1/24/2022	Buy	22,707	$4.69	$106,495.83
1/20/2022	Buy	20,000	$5.17	$103,400.00
1/18/2022	Buy	10,000	$5.08	$50,800.00
1/13/2022	Buy	19,953	$5.13	$102,358.89
1/11/2022	Buy	10,845	$5.18	$56,177.10
12/28/2021	Buy	11,288	$5.28	$59,600.64
12/23/2021	Buy	11,000	$5.27	$57,970.00
12/17/2021	Buy	117	$5.29	$618.93
4/19/2021	Buy	1,965	$13.38	$26,291.70
4/7/2021	Buy	2,000	$14.00	$28,000.00
3/23/2021	Buy	10,000	$14.34	$143,400.00
3/8/2021	Buy	1,000	$15.25	$15,250.00
2/23/2021	Buy	20,300	$17.79	$361,137.00

James Peyer Buying and Selling Activity at Sensei Biotherapeutics

Sensei Biotherapeutics Company Overview

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Today's Range

Now: $0.50

$0.46

$0.53

50 Day Range

MA: $0.52

$0.42

$0.78

2 Week Range

Now: $0.50

$0.38

$1.94

Volume

440,578 shs

Average Volume

441,992 shs

Market Capitalization

$12.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.06